Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2014


Academic Discovery Workshop

23 Sep 2014 - 25 Sep 2014 - Baltimore, MD, USA



Bookmark and Share


The drug discovery landscape is facing many challenges and changes fueled in part with the ongoing de-risking efforts by the Pharma industry; seemingly downsizing their footprint or exiting the space all together. The emerging new paradigm seems to be revolving around academic and non-for-profit institutions to carry out the discovery part of the process across a multitude of therapeutic areas. What has started as a successful interactive workshop for academic screening for the past three years, has now evolved to encompass all discovery aspects from technology development, hit identification, to licensing deals.

This new format will continue to provide delegates the opportunity to learn as well as share experiences about enabling technologies, hit to lead generation, dealing with academic tech transfer offices, identifying and working with CROs, and interrogating the value proposition of functional genomics in translational research. Organised by Dr Hakim Djaballah, Director of the HTS Core Facility at Memorial Sloan Kettering Cancer Center, our 4th Annual Academic Discovery Workshop will take place at the Sheraton Baltimore North in Baltimore from September 23rd-25th. Whether delegates are looking to expand their knowledge, engage in discussions with thought leaders during the afternoon panel discussion sessions, or simply requiring more of an insight to aid and foster future collaborations, this workshop together with the newly established short courses is highly recommended to anyone working or has an interest in drug discovery from academia, research institutes, biotech, and Pharma companies.

The workshop also aims to help energize the discovery paradigm through open panel discussions on highly provocative topics such as “Target-based versus phenotypic-based drug discovery”, “Functional genomics technologies and their impact of target identification”, or "private-public partnerships". it is hoped that through these kind of open discussions, delegates will have the opportunity to build their own consensus and bring their points of view across. We are always seeking new ideas and inputs to help discover novel or repurpose known drugs to fight disease whether in a pharmaceutical or academic setting.

Agenda Topics:

  • Academic Technology Transfer: Due Diligence, Development and Commercialisation
  • Building and Financing Drug Discovery Efforts in Academia
  • Functional Genomics Technologies in 2014
  • Identifying and Working with CRO's
  • Novel and Enabling Screening Technologies in 2014
  • Public - Private Partnerships
  • RNAi and Genome Editing Technologies
  • Target versus Phenotypic Based Discovery
  • Vendor/User Perspectives on HCA in 2014




Further information
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!